For much of the Great Recession and beyond, biotechnology was out of favor among angel and venture capitalists. Software and Internet deals became the shiny object for investors who wanted faster returns with fewer dollars risked.To fatigued life sciences investors, biotech seemed a bit like last year’s prom date — expensive, time-consuming and generally “high maintenance” because of the seemingly endless regulatory challenges faced by emerging companies.
Hey, check out all the research scientist jobs. Post your resume today!
